share_log

JP Morgan Reinstates Neutral on Agios Pharmaceuticals, Announces $46 Price Target

Benzinga ·  Jun 14 05:07

JP Morgan analyst Tessa Romero reinstates Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and announces $46 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment